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RESULTS: Compared to the combined control groups, sig-
nificant long-term benefit attributable to the occupational
therapy intervention was found for six of the eight SF-36
domain scores: body pain, role functioning, vitality, social
functioning, role emotional, general mental health (p 
0.05). When we compared the occupational therapy group
with the combined control group, the incremental cost-
effectiveness ratio was $17,476 per QALY. Sensitivity anal-
yses confirmed that these quantitative results were robust.
OUTCOMES RESEARCH METHODS
RM1
CONTROLLING FOR SIMULTANEITY BIAS IN 
OUTCOME STUDIES USING PANEL DATA
Luo R, Hay J, Hsiao C
The University of Southern California, Los Angeles, CA, USA
In outcome studies, healthcare costs and health status are
two focuses of primary interest. These two variables in-
teract with each other: change in health status results in
healthcare utilization and healthcare utilization has impact
on health status. This interaction necessitates a statistical
simultaneous modeling. Ignoring such endogeneity could
lead to inappropriate conclusions. Often, outcomes data
from clinical trials consist of panel data in which out-
comes are repeatedly measured over time. The nature of
panel data complicates statistical modeling to control for
this endogeneity bias.
OBJECTIVE: To present a statistical model and an esti-
mation procedure that are most suitable to tackling the
endogeneity between healthcare costs and health status
by using panel data from clinical trials.
METHOD: A simultaneous error-component model is
established as:
<1>
<2>
where
The dependent variable and are the health expenditure and
health status of individual i (i  1, 2,. . ., N) at time t (t 
1,. . ., T); Xit is the vector of the common exogenous vari-
ables in both the cost and health equations; z1it is the vec-
tor of explanatory variables included in the cost equation
but not the health equation; z2it is the vector of explana-
tory variables included in the health equation but not the
cost equation.  are the unknown parameters; v1it and v2it
and are the unobserved disturbances which consist of 
i,
the component from an individual unit, t, the component
from a time period, uit, the independently identically dis-
tributed random disturbance. Given the structure of the
disturbances in the model, we propose the error-compo-
cit hitβ11 Xitβ12 zlitβ13 vlit+++=
hit citβ21 Xitβ22 z2itβ23 v2it+ + +=
v1it α1i λ1t u1it+ +=
v2it α2i λ2t u2it+ +=
nent three-stage least-squares method to estimate this
model.
IMPLICATION: This paper provides an example of
modeling costs and health status simultaneously using
panel data from clinical trials.
RM2
COSTS OF HEALTHCARE FOR 8 YEARS PRIOR 
TO RECOGNITION OF TYPE 2 DIABETES (DM2)
Nichols GA, Brown JB
Center for Health Research, Portland, OR, USA
Type 2 Diabetes and its complications lead to higher
medical care costs, beginning at diagnosis and continuing
throughout life. But little is known about healthcare ex-
penditures and utilization prior to recognition of DM2.
We identified all members of Kaiser Permanente North-
west Region, a nonprofit HMO, diagnosed with DM2 in
1988 through 1995, and matched each of them to an
HMO member without DM based on age, gender, and
eligibility. We then observed outpatient, pharmaceutical,
and inpatient costs in the 8 years prior to diagnosis and
calculated incremental costs as the difference between
DM2s and their matched controls. Total costs for DM2s
and their matched controls were relatively flat 4 to 8 years
prior to diagnosis of DM2; incremental costs were not sig-
nificantly different from zero in those years. In the 3 years
immediately before diagnosis, however, DM2 costs rose
while control costs remained flat. By this measure, DM2
appears to cause significant excess total costs, starting
about 3 years prior to diagnosis. Considered on their own,
though, outpatient and pharmacy costs each exceeded
control costs during all 8 pre-diagnostic years. The major-
ity of incremental costs were for outpatient visits (62%).
We conclude that DM2 begins causing greater health ex-
penditures at least 8 years before diagnosis.
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Per-person medical costs by year prior to diagnosis of DM2
No. of
cases
Pre-DX
year
DM2
costs ($)
Control
costs ($)
Incremental
costs ($)
Percent
incremental (%)
708 	8 1774 1712 62 3%
1493 	7 2144 1767 377 18%
2397 	6 1872 1792 80 4%
3323 	5 2208 2005 203 9%
4269 	4 2238 2044 194 9%
5327 	3 2474 1911 563 23%
6490 	2 2536 1978 558 22%
8685 	1 2819 1949 870 31%
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OBJECTIVE: This retrospective study examined both the
use of abciximab treatment and its impact on hospital
length of stay among angioplasty patients enrolled in
managed care organizations.
METHODS: Retrospective billing data was obtained for
a sample of 1847 angioplasty patients who were enrolled
in US managed care organizations. Multivariate analysis
was used to control for a wide range of factors (patient
demographics, comorbidities, admission and discharge
information, and hospital characteristics such as region
of the country, size, number of angioplasties performed
per year) that may influence a patient’s likelihood of re-
ceiving abciximab or impact their length of stay in the
hospital. Estimation was conducted via a two-stage sam-
ple selection model.
RESULTS: Patients in poorer health were more likely to
receive abciximab. After controlling for high-risk indica-
tions and selection bias, results indicate that in contrast
with studies involving other payers, women and minori-
ties enrolled in these managed care organizations had the
same access to abciximab as other members. Further-
more, results indicate that angioplasty patients who were
given abciximab had a significantly shorter length of stay
(0.59 fewer days  0.24 days) than those patients who
did not receive abciximab.
CONCLUSIONS: These findings indicate that there are
potential economic benefits for hospitals administering ab-
ciximab. Given that hospital length of stay has been found
to be one of the most important determinants of total
healthcare costs, the reduced length of stay found in this
study implies cost off-sets for patients receiving abciximab.
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OUTCOME ASSESSMENT OF A FALL 
RISK-REDUCTION PROGRAM: 
METHODOLOGICAL ISSUES
Maynard PW1, Slattum PW1,2
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OBJECTIVE: To determine the outcomes associated with
a falls risk-reduction program.
METHODS: Medical and pharmacy claims data for
33,208 Medicare supplemental insurance plan patients
 75 years of age were evaluated. Each patient’s individ-
ual diagnosis- and drug-related risk factors were analyzed,
and providers for those patients at greatest risk received a
patient-specific educational intervention. Intermediate out-
comes (the mean number of high-risk drugs and the total
number of drugs prescribed) were evaluated before and for
9 months post-intervention in a study population of 1818
patients.
RESULTS: Pre-intervention there was a trend of escalat-
ing drug use in this population. Post-intervention, there
was a reduction (p  0.01) in the mean number of drugs
(	0.61) and high-risk drugs (	0.49). A retrospective
comparison population of 2211 patients showed an in-
crease (p  0.01) in the mean number of drugs (2.2)
and high-risk drugs (0.77) prescribed over a similar
time interval. Regression to the mean and selective mor-
tality do not appear to account for the results observed.
Examining the medical and economic benefits resulting
from this reduction in drug use has proven to be prob-
lematic. Falls are poorly documented in claims data.
Consequences of falls (e.g. hip fracture) can be identified
through claims review, but the incidence of these conse-
quences is relatively low, and differentiation between ini-
tial and follow up care is difficult. Several comparison
populations were evaluated for use in outcomes assess-
ment, but each has significant limitations. Also, medical
and economic benefits from a risk-reduction program
would be expected to accrue over an extended period of
time.
CONCLUSION: The intervention impacted the interme-
diate outcomes, but barriers prohibited analysis of poten-
tial medical and economic benefits.
NEW ECONOMIC RESEARCH METHODS
ER1
THE APPLICATION OF MULTILEVEL 
MODELING AND CLUSTER ANALYSIS
TO MULTINATIONAL ECONOMIC 
EVALUATION DATA
Pang F
Centre for Health Economics, University of York, York, UK
OBJECTIVE: Although economic evaluations are increas-
ingly conducted on a multinational basis, the issue of how
to analyze and interpret multinational economic data has
received little attention. This research illustrates the use of
cluster analysis to investigate patterns in resource utiliza-
tion between different countries or centers, and examines
the use of multilevel modeling to explicitly detect a hierar-
chical structure to the data if one is present and to explore
the relationship between site and outcome.
METHODS: The cluster analysis and multilevel model-
ing using SPSS for Windows and MLn, were based upon
resource utilization data captured in a multinational
phase III randomized controlled trial of two alternative
drug treatments for rheumatoid arthritis. In this trial,
data (e.g., inpatient episodes, outpatient visits, therapeu-
tic procedures, diagnostic procedures, GP visits, physio-
therapy sessions) were collected for 374 patients over a
108-week period, enrolled at 56 centers in nine European
countries. Clustering was investigated employing various
linkage and distance measures, and parameters were esti-
mated for the multilevel model specified with countries as
level 3 units, centers as level 2 units, and patients as level
1 units.
RESULTS: A variety of clustering solutions were gener-
ated according to the resource category examined and
visually presented in dendrogramatic form and icicle
plots. Across all categories, the countries resolved into
